Subgroup analyses
| Subgroup | Patients n | HR (95% CI) | p-value for interaction |
| Sex | |||
| Female | 557 | 1.58 (1.18–2.10) | 0.67 |
| Male | 833 | 1.39 (1.14–1.69) | |
| Age | |||
| <70 years | 1000 | 1.30 (1.07–1.57) | 0.09 |
| ≥70 years | 526 | 1.70 (1.28–2.24) | |
| Histology | |||
| SQ | 512 | 1.47 (1.12–1.94) | 0.62 |
| AD | 718 | 1.52 (1.19–1.95) | |
| LC | 296 | 1.30 (0.94–1.79) | |
| SQ# | 512 | 1.42 (1.10–1.84) | 0.81 |
| AD# | 718 | 1.53 (1.20–1.95) | |
| LC# | 296 | 1.31 (0.95–1.80) | |
| Disease stage | |||
| I | 766 | 1.60 (1.18–2.17) | 0.05 |
| II | 117 | 2.59 (1.25–5.39) | |
| III | 475 | 1.31 (1.04–1.64) | |
| IV | 168 | 0.98 (0.70–1.38) | |
| Surgery | |||
| No | 481 | 1.25 (1.00–1.55) | 0.15 |
| Yes | 1045 | 1.55 (1.25–1.94) |
SQ: squamous cell carcinoma; AD: adenocarcinoma; LC: large cell carcinoma. #: threshold for dichotomising SUV dependent on histology (per study).